Health Technology · Pharmaceuticals: Generic · NSE: JAGSNPHARM · data 2026-10-09
Jagsonpal Pharmaceuticals Ltd.
Health check: Strong (7.1/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹225.6
Market cap
₹1,521 cr
P/E
33.7
P/B
—
ROE
16.7%
ROCE
18.1%
Debt / equity
0.03
Dividend yield
1.08%
1-year return
3.3%
52-week high
₹264.5
52-week low
₹155
Operating margin
17.7%
Growth
| Revenue (last 12 months) | ₹294 cr |
| Net profit (last 12 months) | ₹45 cr |
| Sales growth, 3 years (yearly) | 6.7% |
| Profit growth, 3 years (yearly) | 17.3% |
Chart patterns
- Double top — forming (key level ₹217.81)
Similar companies
Fermenta Biotech Ltd (FERMENTA) · Accent Microcell Limited (ACCENTMIC) · Q-Line Biotech Limited (QLINE) · Amrutanjan Health Care Limited (AMRUTANJAN) · Anlon Healthcare Limited (AHCL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JAGSNPHARM in NSE Scanner →